[go: up one dir, main page]

WO2000072023A3 - Diagnosis and treatment of atherosclerosis and coronary heart disease - Google Patents

Diagnosis and treatment of atherosclerosis and coronary heart disease Download PDF

Info

Publication number
WO2000072023A3
WO2000072023A3 PCT/IB2000/000688 IB0000688W WO0072023A3 WO 2000072023 A3 WO2000072023 A3 WO 2000072023A3 IB 0000688 W IB0000688 W IB 0000688W WO 0072023 A3 WO0072023 A3 WO 0072023A3
Authority
WO
WIPO (PCT)
Prior art keywords
atherosclerosis
diagnosis
treatment
heart disease
coronary heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2000/000688
Other languages
French (fr)
Other versions
WO2000072023A2 (en
Inventor
Mahavir Singh
Zoltan Prohaszka
Gyorgy Fust
Laszlo Romics
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SEMMELWEIS UNIVERSITY OF MEDICINE
SEMMELWEIS UNIVERSITY OF MEDIC
Original Assignee
SEMMELWEIS UNIVERSITY OF MEDICINE
SEMMELWEIS UNIVERSITY OF MEDIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SEMMELWEIS UNIVERSITY OF MEDICINE, SEMMELWEIS UNIVERSITY OF MEDIC filed Critical SEMMELWEIS UNIVERSITY OF MEDICINE
Priority to CA002373285A priority Critical patent/CA2373285A1/en
Priority to JP2000620360A priority patent/JP2003502289A/en
Priority to KR1020017014790A priority patent/KR20020022669A/en
Priority to EP00927636A priority patent/EP1179182A2/en
Priority to BR0010741-7A priority patent/BR0010741A/en
Priority to AU46025/00A priority patent/AU4602500A/en
Publication of WO2000072023A2 publication Critical patent/WO2000072023A2/en
Publication of WO2000072023A3 publication Critical patent/WO2000072023A3/en
Priority to NO20015653A priority patent/NO20015653L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)

Abstract

The present invention concerns novel uses for human HSP60 in methods of treatment or diagnosis of the human body, more particularly diagnostic test methods, the manufacture of diagnostic tests, and diagnostic test kits for patients with vascular disorders due to atherosclerosis, having a tendency to heat shock protein-induced complement activation, for example to myocardial disorders such as coronary heart disease.
PCT/IB2000/000688 1999-05-21 2000-05-22 Diagnosis and treatment of atherosclerosis and coronary heart disease Ceased WO2000072023A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002373285A CA2373285A1 (en) 1999-05-21 2000-05-22 Diagnosis and treatment of atherosclerosis and coronary heart disease
JP2000620360A JP2003502289A (en) 1999-05-21 2000-05-22 Diagnosis and treatment of atherosclerosis and coronary heart disease
KR1020017014790A KR20020022669A (en) 1999-05-21 2000-05-22 Diagnosis and Treatment of Atherosclerosis and Coronary Heart Disease
EP00927636A EP1179182A2 (en) 1999-05-21 2000-05-22 Diagnosis and treatment of atherosclerosis and coronary heart disease
BR0010741-7A BR0010741A (en) 1999-05-21 2000-05-22 hhsp60 or an immunogenic fragment thereof, diagnostic test method for a tendency to complement activation induced by heat shock protein, uses of hhsp60 and a member of the hsp60 protein family, other than hhsp60, and of antigen presenting an epitope unique for hhsp60 and that does not have any shared hsp60 epitopes, diagnostic test kit for patients who have a tendency to complement activation induced by heat shock protein, and methods of manufacturing a drug for the treatment of induced complement activation by heat shock protein, and to identify a compound or substance or agent that inhibits hhsp60-induced complement activation
AU46025/00A AU4602500A (en) 1999-05-21 2000-05-22 Diagnosis and treatment of atherosclerosis and coronary heart disease
NO20015653A NO20015653L (en) 1999-05-21 2001-11-20 Diagnosis and treatment of atherosclerosis and coronary heart disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9911772.3A GB9911772D0 (en) 1999-05-21 1999-05-21 Diagnosis and treatment of atherosclerosis
GB9911772.3 1999-05-21

Publications (2)

Publication Number Publication Date
WO2000072023A2 WO2000072023A2 (en) 2000-11-30
WO2000072023A3 true WO2000072023A3 (en) 2001-04-05

Family

ID=10853840

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/000688 Ceased WO2000072023A2 (en) 1999-05-21 2000-05-22 Diagnosis and treatment of atherosclerosis and coronary heart disease

Country Status (13)

Country Link
EP (1) EP1179182A2 (en)
JP (1) JP2003502289A (en)
KR (1) KR20020022669A (en)
CN (1) CN1351713A (en)
AU (1) AU4602500A (en)
BR (1) BR0010741A (en)
CA (1) CA2373285A1 (en)
GB (1) GB9911772D0 (en)
HU (1) HUP0201568A2 (en)
NO (1) NO20015653L (en)
RU (1) RU2001134499A (en)
WO (1) WO2000072023A2 (en)
ZA (1) ZA200109544B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077279A1 (en) * 2001-10-24 2003-04-24 Cedars-Sinai Medical Center Methods for treating vascular disease by inhibiting toll-like receptor-4
ES2315034B1 (en) * 2004-07-02 2009-12-30 Laboratorios Indas, S.A. THERMAL SHOCK PROTEIN 27 (HSP-27) AS A CARDIOVASCULAR DISEASE MARKER.
CU23504A1 (en) 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech PEPTIDES AND DERIVATIVES APL TYPE OF HSP60 AND PHARMACEUTICAL COMPOSITIONS
JP4283812B2 (en) * 2006-01-06 2009-06-24 財団法人工業技術研究院 Diagnostic method of myasthenia gravis and its kit
US8524453B2 (en) 2006-02-10 2013-09-03 The Brigham And Woman's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
RU2341801C2 (en) * 2006-11-28 2008-12-20 Федеральное государственное учреждение "Федеральный центр сердца, крови и эндокринологии имени В.А. Алмазова Федерального агентства по высокотехнологичной медицинской помощи" Method of antihypertensive therapy efficiency evaluation in patients suffering from essential hypertension
JP4581094B2 (en) * 2006-12-07 2010-11-17 国立大学法人 岡山大学 Testing method for arteriosclerosis
US9512196B2 (en) 2008-09-22 2016-12-06 Cedars-Sinai Medical Center Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
EP2328911A4 (en) 2008-09-22 2012-03-14 Cedars Sinai Medical Center HUMAN MD-2 IN SHORT FORM AS NEGATIVE REGULATOR OF TOLL-4 TYPE RECEIVER SIGNALING
KR102344948B1 (en) * 2018-09-03 2021-12-28 세종대학교산학협력단 Monoclonal antibody N1-A4 specific to human naive pluripotent stem cells
RU2760539C1 (en) * 2021-02-07 2021-11-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пензенский государственный университет" Method for screening diagnosis of coronary atherosclerosis using non-invasive ca-biomarker
WO2024017423A1 (en) * 2022-07-22 2024-01-25 Centro De Ingenieria Genética Y Biotecnología Peptide for the treatment of diseases associated with apolipoprotein ai or transthyretin involvement

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT398495B (en) * 1992-06-09 1994-12-27 Wick Georg Dr Diagnosis or prognosis of atherosclerosis
WO1998008536A2 (en) * 1996-08-30 1998-03-05 Yeda Research And Development Co. Ltd. Method of reducing the severity of host vs. graft reaction by down-regulating hsp60 autoimmunity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT398495B (en) * 1992-06-09 1994-12-27 Wick Georg Dr Diagnosis or prognosis of atherosclerosis
WO1998008536A2 (en) * 1996-08-30 1998-03-05 Yeda Research And Development Co. Ltd. Method of reducing the severity of host vs. graft reaction by down-regulating hsp60 autoimmunity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MAYR M ET AL: "Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: Immune reactions to heat shock proteins as a possible link between infection and atherosclerosis.", CIRCULATION, vol. 99, no. 12, 30 March 1999 (1999-03-30), pages 1560 - 1566, XP000971179 *
PROHASZKA Z ET AL: "Antibodies against human heat-shock protein (hsp) 60 and mycobacterial hsp65 differ in their antigen specificity and complement-activating ability.", INTERNATIONAL IMMUNOLOGY, vol. 11, no. 9, September 1999 (1999-09-01), pages 1363 - 1370, XP000971301 *
SCHETT G ET AL: "Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity.", JOURNAL OF CLINICAL INVESTIGATION, vol. 96, no. 6, 1995, pages 2569 - 2577, XP000971181 *

Also Published As

Publication number Publication date
RU2001134499A (en) 2003-08-27
CN1351713A (en) 2002-05-29
HUP0201568A2 (en) 2002-08-28
WO2000072023A2 (en) 2000-11-30
NO20015653L (en) 2002-01-17
BR0010741A (en) 2002-02-19
AU4602500A (en) 2000-12-12
NO20015653D0 (en) 2001-11-20
GB9911772D0 (en) 1999-07-21
EP1179182A2 (en) 2002-02-13
KR20020022669A (en) 2002-03-27
JP2003502289A (en) 2003-01-21
ZA200109544B (en) 2002-06-20
CA2373285A1 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
EP2071040A3 (en) Diagnostics and therapeutics for vascular disease
WO2000072023A3 (en) Diagnosis and treatment of atherosclerosis and coronary heart disease
EP0909814A3 (en) Use of protein kinases for the diagnosis and treatment of Alzheimer's disease
WO2002040634A3 (en) Expression miniarrays and uses thereof
EP1532269A4 (en) 1L1RL-1 AS A MARKER OF CARDIOVASCULAR DISEASES AND THERAPEUTIC TARGET
ATE514389T1 (en) ABLATION CATHETER
CA2274596A1 (en) Compositions and methods for enhancing intestinal function
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
IS2522B (en) Antibodies for ED-B Fibronectin Boxes, Compositions Containing Them, and Their Use for Diagnosis and Treatment of Tumors and Diseases Associated with Vascular Anatomy
EP2006298A3 (en) Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof
WO2004066805A3 (en) In vivo device for improving diastolic ventricular function
WO1999058098A3 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
BRPI0411353A (en) modified corina molecules having surrogate activation sequences and applications thereof
ATE218856T1 (en) AMINOTETRALIN DERIVATIVE FOR THE TREATMENT OF CARDIOVASCULAR DISEASE
AU5960890A (en) Use of creatine kinase and its isozyme ck-mb and human ventricular myosin light chain 1 in the diagnosis of heart failure
JP2000352566A5 (en)
WO2000061196A3 (en) Fatty acid analogs for diagnosis of coronary artery disease
FR2828212B1 (en) METHODS OF DIAGNOSING AND PROGNOSING PARKINSON'S DISEASE
AU2784695A (en) Complex compounds for diagnosis of vascular diseases
WO2001055692A3 (en) Neurosteroids as markers for alzheimer's disease
WO2003053364A3 (en) Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908
WO2004071411A3 (en) Methods and compositions in treating pain and painful disorders using 16386, 15402, 21165, 1423, 636, 12303, 21425, 27410, 38554, 38555, 55063, 57145, 59914, 94921, 16852, 33260, 58573, 30911, 85913, 14303, 16816, 17827 or 32620
Akiyama et al. Ashman phenomenon of the T wave
Menown et al. Body surface vector mapping for early diagnosis of acute myocardial infarction with left bundle branch block
RU96104134A (en) METHOD FOR DIAGNOSTIC OF SEXUAL SADISTIC DRIVING IN MEN WITH EARLY ORGANIC BRAIN DISORDERS

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00807857.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000927636

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/01360/MU

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2373285

Country of ref document: CA

Ref document number: 2373285

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09979489

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2000 620360

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017014790

Country of ref document: KR

Ref document number: 46025/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000927636

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017014790

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1020017014790

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2000927636

Country of ref document: EP